The role of vitamin D deficiency in sepsis and potential therapeutic implications

Journal of Infection

Volumn 63, Issue 5, 2011, Pages 321-326

  Watkins, Richard R ^a   Yamshchikov, Alexandra V ^b   Lemonovich, Tracy L ^c   Salata, Robert A ^c  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Adaptive immunity; Cathelicidin; Infection; Innate immunity; Review; Sepsis; Therapy; Vitamin D deficiency; Vitamin D receptor

Indexed keywords

CALCITRIOL; CATHELICIDIN; VITAMIN D; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; BACTEREMIA; DISEASE ASSOCIATION; FUNGEMIA; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; INFECTION RISK; INNATE IMMUNITY; NONHUMAN; PROTEIN BINDING; REVIEW; SEPSIS; SEPTIC SHOCK; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN INTAKE;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; RECEPTORS, CALCITRIOL; SEPSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 80054056860     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.07.002     Document Type: Review

References (62)

1. Khajavi A., Amirhakimi G.H. The rachitic lung: pulmonary findings in 30 infants and children with malnutritional rickets. Clin Pediatr 1977, 16:36-38.
2. Chesney R.W. Vitamin D and the magic mountain: the anti-infectious role of the vitamin. J Peds 2010, 156:698-703.
3. Bartley J. Vitamin D: emerging roles in infection and immunity. Expert Rev Anti Infect Ther 2010, 8:1359-1369.
4. Holick M.F. Vitamin D deficiency. NEJM 2007, 357:266-281.
5. Tangpricha V., Pearce E.N., Chen T.C., Holick M.F. Vitamin D deficiency among free-living healthy young adults. Am J Med 2002, 112:659-662.
6. Grant W.B. Solar ultraviolet-B irradiance and vitamin D may reduce the risk of septicemia. Dermato-Endocrinology 2009, 1:1-6.
7. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1776.
8. Lange N.E., Litonjua A., Hawrylowicz C.M., Weiss S. Vitamin D., the immune system and asthma. Expert Rev Clin Immunol 2009, 5:693-702.
9. Adams J.S., Hewison M. Unexpected actions of vitamin D: new prospectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008, 4:80-90.
10. Walker V.P., Modlin R.L. The vitamin D connection to pediatric infections and immune function. Pediatr Res 2009, 65:106-113.
11. Yim S., Dhawan P., Ragunath C., Christakos S., Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1, 25-dihydroxyvitamin D3. J Cyst Fibros 2007, 6:403-410.
12. Adams J. Vitamin D as a defensin. J Musculoskelet Neuronal Interact 2006, 6:344-346.
13. Liu P.T., Stenger S., Tang D., Modlin R.L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007, 179:2060-2063.
14. Mahon B.D., Wittke A., Weaver V., Cantorna M.T. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003, 89:922-932.
15. Adorini L., Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol 2009, 70:345-352.
16. Kamen D.L., Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med 2010, 88:441-450.
17. Reichel H., Koeffler H.P., Tobler A., Norman A.W. 1 α,25-dihydroxyvitamin D3 inhibits γ-interferon synthesis by normal human peripheral blood lymphocytes. PNAS 1987, 84:3385-3389.
18. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179:1634-1647.
19. Heine G., Niesner U., Chang H.D., Steinmeyer A., Zugel U., Zuberbier T., et al. 1,25-dihydroxyvitamin D3 promotes IL-10 production in human B cells. Eur J Immunol 2008, 38:2210-2218.
20. Hypponen E., Berry D.J., Wjst M., Power C. Serum 25-hydroxyvitamin D and IgE-a significant but nonlinear relationship. Allergy 2009, 64:613-620.
21. Finland M., Jones W.F., Barnes M.W. Occurrence of serious bacterial infections since the introduction of antibacterial agents. JAMA 1959, 84:2188-2197.
22. Kreger B.E., Craven D.E., McCabe W.R. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980, 68:344-355.
23. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. NEJM 2003, 348:1546-1554.
24. Wesche-Soldato D.E., Swan R.Z., Chung C.S., Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007, 8:493-500.
25. Novotny N.M., Lahm T., Markel T.A., Crisostomo P.R., Wang M., Wang Y., et al. β-Blockers in sepsis: reexamining the evidence. Shock 2009, 31:113-119.
26. Angus D.C., Linde-Zwirble W.T., Lindicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
27. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008, 2008(34):17-60.
28. Leung B., Harris H.W. NKT cells in sepsis. Clin Devel Immunol 2010, 414650.
29. Riedemann N.C., Guo R.F., Ward P.A. Novel strategies for the treatment of sepsis. Nat Med 2003, 9:517-524.
30. Sweet M.J., Hume D.A. Endotoxin signal transduction in macrophages. J Leukoc Biol 1996, 60:8-26.
31. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. PNAS 2000, 97:13766-13771.
32. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999, 16:10689-10692.
33. Yu S., Cantorna M.T. The vitamin D receptor is required for iNKT cell development. PNAS 2008, 105:5207-5212.
34. Nierman D.M., Mechanick J.I. Bone hyperresorption is prevalent in chronically critically ill patients. Chest 1998, 114:1122-1128.
35. Berghe G., Van Roosbroeck D., Vanhove P., Wouters P.J., De Pourcq L., Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 2003, 88:4623-4632.
36. Asakura H., Aoshima K., Suga Y., Yamazaki M., Morishita E., Saito M., et al. Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models. Thromb Haemost 2001, 85:287-290.
37. Moller S., Laigaard F., Olgaard K., Hemmingsen C. Effect of 1,25-dihydroxy-vitamin D3 in experimental sepsis. Int J Med Sci 2007, 4:190-195.
38. Horiuchi H., Nagata I., Komoriya K. Protective effect of vitamin D3 analogues on endotoxin shock in mice. Agents Actions 1991, 33:343-348.
39. Deitch E.A. Animal models of sepsis and septic shock: a review and lessons learned. Shock 1998, 9:1-11.
40. Watt G.H., Ashton S.H., Cook J.A., Wise W.C., Halushka P.V., Galbraith R.M. Alterations in plasma levels and complexing of Gc (vitamin D-binding protein) in rats with endotoxic shock. Circ Shock 1989, 28:279-291.
41. Equils O., Naiki Y., Shapiro A.M., Michelsen K., Lu D., Adams J., et al. 1,25-dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol 2006, 143:58-64.
42. Bukoski R.D., Xue H. On the vascular inotropic action of 1,25-(OH)2 vitamin D3. Am J Hypertens 1993, 6:388-396.
43. Dahl B., Schiodt F.V., Ott P., Wians F., Lee W.M., Balko J., et al. Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. Crit Care Med 2003, 31:152-156.
44. Jeng L., Yamshchikov A.V., Judd S.E., Blumberg H.M., Martin G.S., Ziegler T.R., et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009, 7:28.
45. McNally J.D., Leis K., Matheson L.A., Karuananyake C., Sankaran K., Rosenberg A.M. Vitamin D deficiency in young children with severe acute lower respiratory infection. Pediatr Pulmonol 2009, 44:981-988.
46. Leow L., Simpson T., Cursons R., Karalus N., Hancox R.J. Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology 2011, 16:611-616.
47. McKinney J.D., Bailey B.A., Garrett L.H., Peiris P., Manning T., Peiris A.N. Relationship between vitamin D status and ICU outcomes in veterans. J Am Med Dir Assoc 2011, 12:208-211.
48. Ginde A.A., Camargo C.A., Shapiro N.I. Vitamin D insufficiency and sepsis severity in emergency department patients with suspected infection. Acad Emerg Med 2011, 18:551-554.
49. Danai P.A., Sinha S., Moss M., Haber M.J., Martin G.S. Seasonal variation in the epidemiology of sepsis. Crit Care Med 2007, 35:410-415.
50. Bischof M.G., Heinze G., Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res 2006, 66:211-215.
51. MacLaughlin J., Holick M.F. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Inves 1985, 76:1536-1538.
52. Barnato A.E., Alexander S.L., Linde-Zwirble W.T., Angus D.C. Racial variation in the incidence, care and outcomes of severe sepsis: analysis of population, patient and hospital characteristics. Am J Respir Crit Care Med 2008, 177:279-284.
53. Grant W.B. Lower vitamin D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. J Natl Med Assoc 2006, 98:357-364.
54. Giovannucci E., Liu Y., Willett W.C. Cancer incidence and mortality and vitamin D in black and white male health professionals. Cancer Epidemiol Biomarkers Prev 2006, 15:2467-2472.
55. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-1402.
56. Steiner S., Speidl W.S., Pleiner J., Seidinger D., Zorn G., Kaun C., et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005, 111:1841-1846.
57. Tleyjeh I.M., Kashour T., Hakim F.A., Zimmerman V.A., Erwin P.J., Sutton A.J., et al. Statins for prevention and treatment of infections. Arch Intern Med 2009, 169:1658-1667.
58. Perez-Castrillon J.L., Vega G., Abad L., Sanz A., Chaves J., Hernandez G., et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007, 99:903-905.
59. Yavuz B., Ertugrul D.T., Cil H., Ata N., Akin K.O., Yalcin A.A., et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?. Cardiovasc Drugs Ther 2009, 23:295-299.
60. Ertugrul D.T., Yavuz B., Cil H., Ata N., Akin K.O., Kucukazman M., et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 2010 Mar 27, [Epub ahead of print].
61. Razzaque M.S. The dualistic role of vitamin D in vascular calcifications. Kidney Int 2011, 79:708-714.
62. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999, 69:842-856.